

---

## Product Data Sheet

---

Product Name: SQ-31765 (SQ31765)

Cat. No.: GC32603

### Chemical Properties

Cas. No. 138383-07-0

SMILES O=C1N(CCN(C)C)C2=CC=CC(C(F)(F)F)=C2C[C@@H](C3=CC=C(OC)C=C3)[C@H]1OC(C)=OFormula  $C_{24}H_{27}F_3N_2O_4$  M.Wt 464.48

Solubility Soluble in DMSO Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure 

### Background

SQ-31765 is a benzazepine calcium channel blocker.

SQ-31765 (SQ 31,765) can reduce the severity of ischemia in a manner which is independent of changes in myocardial blood flow or hemodynamic alterations. Anesthetized dogs are given saline (n=6), SQ-31765 (n=6; 0.2 mg/kg) or SQ 32,189 (n=6; 0.2 mg/kg) i.v. 10 min before ischemia. The effect on pacing-induced ST-segment elevation (pacing+left anterior descending coronary artery stenosis) and myocardial blood flow are determined. SQ-31765 reduces ST-elevation ( $P < 0.05$ ) compared to saline at 10, 40 and 70 min after infusion ( $5.9 \pm 1.4$  and  $12.0 \pm 1.4$  mV, respectively, at 70 min). Left anterior descending coronary artery stenosis during atrial pacing resulted in a significant reduction in subendocardial flow in all groups before drug infusion ( $41 \pm 7$ ,  $44 \pm 7$  and  $35 \pm 9$  mL/min/100 g for saline, SQ-31765 and SQ 32,189, respectively)[1].

[1]. Grover GJ, et al. Anti-ischemic and vasorelaxant effects of the new benzazepine calcium channel blocker SQ 31,765. J Pharmacol Exp Ther. 1989 Dec;251(3):1020-5.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---